Summary of Research: Development and Validation of the Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ)
AbstractThis is a summary of the original article ‘Development and Validation of the Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ)’. Individuals with insomnia are best positioned to assess the impact of insomnia on their quality of life. Patient reported outcomes (PROs) are self-reported health measures created to allow people to record their experience of their disease. Chronic insomnia has a major impact on daytime functioning for patients, and on their quality of life. This summary of research provides an overview of a previously published article detailing the development and evaluation of the Insomni...
Source: Advances in Therapy - May 26, 2023 Category: Drugs & Pharmacology Source Type: research
Abdominopelvic Surgery: Intraoperative Ureteral Injury and Prophylaxis in the United States, 2015 –2019
ConclusionUse of stenting and cystoscopy largely varied by surgery type, as did rates of IUI. The relatively low use of prophylactic measures suggests there may be an unmet need for a safe, convenient method of injury prophylaxis in abdominopelvic surgeries. Development of new tools, technology, and/or techniques is needed to help surgeons identify the ureter and avoid IUI and the resulting complications. Graphical Abstract (Source: Advances in Therapy)
Source: Advances in Therapy - May 25, 2023 Category: Drugs & Pharmacology Source Type: research
Patient Characteristics, Testing and Treatment Patterns, and Outcomes in EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Multinational, Real-World Study
ConclusionThis real-world multinational data set showed that most patients withEGFRm+ aNSCLC were treated per the country relevant clinical guidelines, with progression as the main reason for early treatment discontinuation. For the included countries, these findings may offer a useful benchmark for decision makers to determine future allocation of healthcare resources for patient s withEGFRm+ aNSCLC. (Source: Advances in Therapy)
Source: Advances in Therapy - May 23, 2023 Category: Drugs & Pharmacology Source Type: research
Economic Impact of Recurrent Clostridioides difficile Infection in the USA: A Systematic Literature Review and Cost Synthesis
ConclusionsWhile real-world studies on economic impact of rCDI in the USA suggested a high-cost burden, inconsistency in methodologies and results reporting warranted a component-based cost synthesis approach to estimate the annual medical cost burden of rCDI. Utilizing available literature, we estimated the average annual rCDI-attributable medical costs to allow for consistent economic assessments of rCDI and identify the budget impact on US payers. (Source: Advances in Therapy)
Source: Advances in Therapy - May 21, 2023 Category: Drugs & Pharmacology Source Type: research
Ponatinib vs. Imatinib as Frontline Treatment for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Matching Adjusted Indirect Comparison
ConclusionIn adults with newly diagnosed Ph + ALL, first-line treatment with ponatinib was associated with better outcomes than first-line treatment with imatinib. (Source: Advances in Therapy)
Source: Advances in Therapy - May 19, 2023 Category: Drugs & Pharmacology Source Type: research
Design Development of the SMARTCLIC ®/CLICWISE® Injection Device for Self-Administered Subcutaneous Therapies: Findings from Usability and Human Factor Studies
ConclusionFindings from this research facilitated development of the SmartClic/ClicWise autoinjector device and demonstrated that it could be used safely and effectively by participants representative of the intended-use population of patients, lay caregivers, and HCPs. (Source: Advances in Therapy)
Source: Advances in Therapy - May 18, 2023 Category: Drugs & Pharmacology Source Type: research
Indirect Costs Due to Lung Cancer-Related Premature Mortality in Four European Countries
ConclusionThe results from this study illustrate a decreasing trend in productivity costs of premature mortality due to lung cancer, as illustrated by the decreasing PVFLP between 2010 and 2019. This trend could be driven by a shift in the distribution of deaths towards older age groups due to advancements in the preventative and treatment landscape. These results provide an economic measure of the lung cancer burden which may assist decision-makers in allocating scarce resources amongst competing priorities in the included countries. (Source: Advances in Therapy)
Source: Advances in Therapy - May 17, 2023 Category: Drugs & Pharmacology Source Type: research
Cost-Effectiveness Analysis of Pembrolizumab as an Adjuvant Treatment of Resected Stage IIB or IIC Melanoma in the United States
ConclusionAs an adjuvant treatment of stage IIB or IIC melanoma, pembrolizumab was estimated to reduce recurrence, extend patients ’ life and QALYs, and be cost-effective versus observation at a US willingness-to-pay threshold. (Source: Advances in Therapy)
Source: Advances in Therapy - May 16, 2023 Category: Drugs & Pharmacology Source Type: research
Real-World Apremilast Use for Treatment of Plaque Psoriasis in Italy: Patient Perspective, Characteristics, and Clinical Outcomes from the DARWIN Study
ConclusionsPatients treated with apremilast for 6 months in Italian clinical practice reported improved QoL, clinically relevant improvements in symptoms, high treatment satisfaction, and high treatment persistence. Our data indicate apremilast is a valuable treatment option for moderate plaque psoriasis.Study RegistrationClinicalTrials.gov identifier, NCT04031027. (Source: Advances in Therapy)
Source: Advances in Therapy - May 12, 2023 Category: Drugs & Pharmacology Source Type: research
An Economic Analysis of Transjugular Intrahepatic Portosystemic Covered Stent Shunt for Variceal Bleeding and Refractory Ascites in a Spanish Setting
ConclusionsTIPSS is likely to be a cost-effective and a cost-saving treatment in patients with cirrhosis in indications 1 and 2, compared with standard treatments. The analyses estimate clinical benefits along with reduced healthcare costs from avoided downstream resource consumption. (Source: Advances in Therapy)
Source: Advances in Therapy - May 9, 2023 Category: Drugs & Pharmacology Source Type: research
Eliciting Patient Insights on the Burden of Nontuberculous Mycobacterial Lung Disease (NTM-LD) and Healthcare Gaps in Germany Through Qualitative Semi-structured Interviews
ConclusionsNTM-LD can considerably impair the lives of patients and their families and/or caregivers. A multidisciplinary approach and establishment of more widespread regional expert centers for NTM-LD management in Germany with well-structured referral and communication pathways accompanied by peer-to-peer support of patient advocacy groups are urgently needed. (Source: Advances in Therapy)
Source: Advances in Therapy - May 8, 2023 Category: Drugs & Pharmacology Source Type: research
Safety and Effectiveness of Vedolizumab in Patients with Moderate-to-Severe Ulcerative Colitis: An Interim Analysis of a Japanese Post-Marketing Surveillance Study
ConclusionThe results confirm a safety and effectiveness profile of vedolizumab consistent with that observed in previous trials.Clinical Trial RegistrationJapicCTI-194603, NCT03824561. (Source: Advances in Therapy)
Source: Advances in Therapy - May 4, 2023 Category: Drugs & Pharmacology Source Type: research
Proton Pump Inhibitors, Kidney Damage, and Mortality: An Updated Narrative Review
AbstractSince their approval by the Food and Drug Administration (FDA) in 1989, proton pump inhibitors (PPIs) have become one of the most highly utilized drugs in the United States, assuming a position as one of the top 10 most prescribed medications in the country. The purpose of PPIs is to limit the amount of gastric acid secreted by the parietal cells via irreversible inhibition of the H+/K+-ATPase pump, therefore maintaining an elevated gastric acid pH of greater than 4 for 15 –21 h. Even though PPIs have many clinical uses, they are not without their adverse effects, mimicking achlorhydria. Besides electrolyte abno...
Source: Advances in Therapy - May 4, 2023 Category: Drugs & Pharmacology Source Type: research
Real-World Modifications of Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Hyperkalemia Initiating Sodium Zirconium Cyclosilicate Therapy: The OPTIMIZE I Study
ConclusionConsistent with clinical trial findings, nearly 80% of patients who initiated SZC for HK optimized their RAASi therapy. Patients may require long-term SZC therapy to encourage continuation of RAASi therapy especially after inpatient and ED visits. (Source: Advances in Therapy)
Source: Advances in Therapy - May 4, 2023 Category: Drugs & Pharmacology Source Type: research
Patient Management and Clinical Outcomes Associated with a Recorded Diagnosis of Stage 3 Chronic Kidney Disease: The REVEAL-CKD Study
ConclusionsA recorded CKD diagnosis was associated with significant improvements in CKD management and monitoring practices and attenuated eGFR decline. Recorded diagnosis of stage 3 CKD is an important first step to reduce the risk of disease progression and minimize adverse clinical outcomes.Trial RegistrationClinicalTrials.gov identifier, NCT04847531. (Source: Advances in Therapy)
Source: Advances in Therapy - May 3, 2023 Category: Drugs & Pharmacology Source Type: research
